EICHOR
● Active Not Recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Condition: Sickle Cell Disease · Sponsor: Agios Pharmaceuticals, Inc.
About this study
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (91)
| University of California San Diego | La Jolla, California, United States | — |
| UCLA Health | Los Angeles, California, United States | — |
| Children's Hospital Oakland | Oakland, California, United States | — |
| University of Connecticut Health Center | Farmington, Connecticut, United States | — |
| Children's National Hospital | Washington D.C., District of Columbia, United States | — |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| Sylvester Comprehensive Cancer Center-Miami | Miami, Florida, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Riley Hospital For Children | Indianapolis, Indiana, United States | — |
| LSU Health Sciences Center - Shreveport | Shreveport, Louisiana, United States | — |
| National Heart Lung and Blood Institute | Bethesda, Maryland, United States | — |
| Kaiser Permanente - Largo Medical Center | Largo, Maryland, United States | — |
+ 79 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05031780